Improved Care for Patients with Moderate-to-Severe Asthma: Reflecting on Errors and Missed Opportunities

Program Overview

The goal of this activity is to foster recognition of missed opportunities and suboptimal care among patients with moderate-to-severe asthma, thereby helping clinicians who treat these patients to examine best practices for management.

Credit Expired

CE Credit Expired

Expires: December 30, 2020

Target Audience

The target audience for this activity is allergy/immunology and pulmonology physicians practicing outside of the United States, who manage patients with moderate-to-severe asthma.

Educational Objectives

Upon successful completion of this educational activity, participants should be better able to:

Distinguish between the different types of asthma based on underlying pathophysiology and biomarkers of disease in order to make personalized treatment decisions
Identify patients with poorly-controlled or difficult-to-treat asthma who are eligible for step-up therapies, including new and emerging biologics
Incorporate new and emerging targeted biologics into the management of patients with severe or poorly-controlled asthma, when appropriate

Activity Faculty

Ratko Djukanovic, MD, DM, FRCP (Chair)

Professor, Medicine
Director, Southampton NIHR Respiratory Biomedical Research Unit
Director, NIHR Southampton Centre for Biomedical Research
Southampton, UK

Stephen P. Peters, MD, PhD, FAAAAI, FACP, FCCP, FCPP

Thomas H. Davis Chair, Pulmonary Medicine
Chief, Section on Pulmonary, Critical Care, Allergy & Immunologic Diseases
Professor, Internal Medicine, Pediatrics and Translational Science
Wake Forest Baptist Health
Winston-Salem, NC

Michael E. Wechsler, MD, MMSc

Co-Director, The Cohen Family Asthma Institute
Professor, Department of Medicine
National Jewish Health
Denver, CO

Featured RMEI CE Activities

Improved Care for Patients with Moderate-to-Severe Asthma: Reflecting on Errors and Missed Opportunities

Program Overview

Target Audience

Educational Objectives

Activity Faculty

Ratko Djukanovic, MD, DM, FRCP (Chair)

Stephen P. Peters, MD, PhD, FAAAAI, FACP, FCCP, FCPP

Michael E. Wechsler, MD, MMSc

Quelling the Vicious Vortex: Targeting Neutrophil Serine Proteases in Non-Cystic Fibrosis Bronchiectasis

Navigating the Frontier of Hematologic Malignancy Therapies. Series of 5 Modules

Cell-Free DNA Potential in Guiding Therapies and Q&A – Module 5

PROTACs: A Paradigm Shift in Drug Discovery – Module 3

Join Our Network

Company

CE Accreditation

HIPAA Verified & Compliant

Subscribe